Does hepatic insulin resistance raise fasting glucose by letting the liver keep producing glucose despite insulin?

The liver plays a central role in blood sugar regulation, acting as the primary source of glucose during fasting periods. In a healthy metabolic state, the hormone insulin acts as a powerful "off switch" for hepatic glucose production. However, hepatic insulin resistance disrupts this regulatory mechanism, leading to elevated fasting glucose levels.

Mechanisms of glucose dysregulation

Under normal conditions, insulin binds to receptors on liver cells, triggering the PI3K-Akt signaling pathway. This pathway phosphorylates a transcription factor called FoxO1, moving it out of the cell nucleus and effectively stopping the production of glucose.

• Enzymatic activation: In hepatic insulin resistance, this signaling fails. FoxO1 remains active in the nucleus, continuously driving the expression of key gluconeogenic enzymes: Phosphoenolpyruvate carboxykinase (PEPCK) and Glucose-6-phosphatase (G6Pase).
• Failed suppression: While insulin normally suppresses endogenous glucose production (EGP) by 80–90%, resistant livers may continue to release glucose at 20–50% of basal rates even when insulin levels are high.

Clinical and metabolic evidence

Research utilizing stable isotope tracer studies confirms that individuals with hepatic insulin resistance exhibit significantly higher fractional gluconeogenesis.

• Correlation with fasting glucose: Markers of hepatic resistance, such as the Hepatic Insulin Resistance Index (HIRI), show a strong positive correlation with fasting plasma glucose (p < 0.001).
• Impact of liver fat: Increased hepatic lipid content is a known driver of this resistance, further impairing the liver's ability to clear insulin and manage glucose output. This creates a paradoxical state where the body has high insulin but the liver continues to produce glucose as if it were "starving."

Bottom line

The claim is fully supported: hepatic insulin resistance causes the liver to ignore insulin’s signal to stop glucose production. This persistent output, driven largely by the FoxO1-PEPCK pathway, is a primary physiological driver of elevated fasting blood sugar and a hallmark of metabolic dysfunction.